Sugi Predict

Sugi Predict / Compounds / SCHEMBL1823581

SCHEMBL1823581

SCHEMBL1823581

OC(=C(O)c1c(O)c(O)c(O)c(O)c1O)c1cccc(O)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 4/20 0.46
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ CA6 P23280 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ ADAMTS4 O75173 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ FYN P06241 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ MMP12 P39900 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ ADAMTS5 Q9UNA0 1/20 0.46
▸ TERT O14746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814415 0.79 ALDH1A1 (0.52) ALDH1A1HPGDCA1CA2HSD17B10
SCHEMBL308224 0.78 HPGD (0.46) ALDH1A1HPGDCA1CA2HSD17B10
SCHEMBL1004754 0.78 HPGD (0.46) ALDH1A1HPGDCA1CA2HSD17B10
SCHEMBL7556755 0.74 TERT (0.52) ALDH1A1HPGDCA1CA2HSD17B10
SCHEMBL8498035 0.74 ALDH1A1 (0.58) ALDH1A1HPGDCA1CA2HSD17B10
SCHEMBL18669900 0.72 TERT (0.46) ALDH1A1HPGDCA1CA2HSD17B10
SCHEMBL10517803 0.71 EGFR (0.47) ALDH1A1HPGDCA1CA2HSD17B10
2,3-Dihydroxybenzoic Acid SCHEMBL37458 0.70 SELL (0.70) ALDH1A1HPGDCA1CA2HSD17B10
2,3-Dihydroxybenzoic Acid SCHEMBL21114367 0.70 SELL (0.70) ALDH1A1HPGDCA1CA2HSD17B10
2,3-Dihydroxybenzoic Acid SCHEMBL29362091 0.70 SELL (0.70) ALDH1A1HPGDCA1CA2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3654929-B1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE OREAL (FR) 2024-05-29 — — EP claimed
EP-3654929-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2020-05-27 — — EP claimed
WO-2019016153-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2019-01-24 — — WO claimed
EP-2315583-B1 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE YVERY (FR) 2018-05-09 — — EP claimed
JP-2011528336-A — — 2011-11-17 — — JP claimed
US-20110184072-A1 FORMULATION INTENDED TO IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE PECHERE LAURENT 2011-07-28 — — US claimed
EP-2315583-A2 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE Yvery (FR) 2011-05-04 — — EP claimed
WO-2010007252-A2 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE YVERY (FR) 2010-01-21 — — WO claimed
EP-3654929-B1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE OREAL (FR) 2024-05-29 — — EP disclosed
EP-3654929-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2020-05-27 — — EP disclosed
WO-2019016153-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2019-01-24 — — WO disclosed
EP-2315583-B1 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE YVERY (FR) 2018-05-09 — — EP disclosed
US-20130029996-A1 SPECIAL COMPOSITION FOR THE USE THEREOF AS A DRUG UNIVERSITE D'AIX-MARSEILLE (FR) 2013-01-31 — — US disclosed
WO-2011089168-A2 SPECIAL COMPOSITION FOR THE USE THEREOF AS A DRUG INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2011-07-28 — — WO disclosed
EP-1064931-A1 Cosmetic composition containing at least an hydroxystilbene and ascorbic acid L'OREAL (FR) 2001-01-03 — — EP disclosed
US-6147121-A TOPICALLY APPLYING HYDROXYSTILBENE DERIVATIVE TO TREAT SKIN AGING AND WRINKLES SOCIETE L'OREAL S.A. (FR) 2000-11-14 — — US disclosed
US-6124364-A Desquamation/epidermal renewal of the skin and/or combating skin aging SOCIETE L'OREAL S.A. (FR) 2000-09-26 — — US disclosed
EP-0953346-A1 Use of at least a hydroxystilbebe in a skin fortifying composition L'OREAL (FR) 1999-11-03 — — EP disclosed
EP-0953345-A1 Use of at least a hydroxystilbene as an agent for decreasing micro-organism adhesion L'OREAL (FR) 1999-11-03 — — EP disclosed
EP-0953344-A1 Use of at least one hydroxystilbene in a composition to stimulate desquamation of the skin and compositions containing it L'OREAL (FR) 1999-11-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184072-A1 FORMULATION INTENDED TO IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE FABP2, SI, SLC10A2 ALDH1A1 1451/4885HPGD 185/4885CA1 4404/4885
US-20130029996-A1 SPECIAL COMPOSITION FOR THE USE THEREOF AS A DRUG PPARG, FABP6, LCT ALDH1A1 659/4885HPGD 37/4885CA1 3802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.